newsfilter
← Earnings
Earnings Releases·

Eloxx Pharmaceuticals — Third Quarter 2026 Earnings Summary

Eloxx Pharmaceuticals reported a net loss of $5.5 million for the third quarter of 2026, driven by increased research and development expenses related to the initiation of its Phase 2b EXACT study for nonsense mutation Alport syndrome. The company dosed its first two patients in this global trial and finalized the protocol for a Phase 2 EXPRESS study targeting nonsense mutation autosomal dominant polycystic kidney disease, with the first patient expected to be dosed in the third quarter of 2027. As of September 30, 2026, Eloxx held $56.3 million in cash and cash equivalents, which management believes will fund operations into 2028. Additionally, the company expanded its leadership team by appointing T.R. Srinivas as Senior Vice President and Chief Medical Officer and added Geno Germano to its Board of Directors.

Company
ELOXX PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology